Linker Information
General Information of This Linker
| Linker ID |
LIN0RWDPB
|
|||||
|---|---|---|---|---|---|---|
| Linker Name |
H- (A114C)-#19 Linker
|
|||||
| Linker Type |
Cathepsin-cleavable linker
|
|||||
| Antibody-Linker Relation |
Cleavable
|
|||||
| Structure |
|
|||||
| Formula |
C29H42N8O6S
|
|||||
| Isosmiles |
CC([C@H](NC(CCCCCNC(C(C=N1)=CN=C1S)=O)=O)C(N[C@@H](CCCNC(N)=O)C(NC2=CC=C(CO)C=C2)=O)=O)C
|
|||||
| InChI |
InChI=1S/C29H42N8O6S/c1-18(2)24(37-23(39)8-4-3-5-13-31-25(40)20-15-33-29(44)34-16-20)27(42)36-22(7-6-14-32-28(30)43)26(41)35-21-11-9-19(17-38)10-12-21/h9-12,15-16,18,22,24,38H,3-8,13-14,17H2,1-2H3,(H,31,40)(H,35,41)(H,36,42)(H,37,39)(H3,30,32,43)(H,33,34,44)/t22-,24-/m0/s1
|
|||||
| InChIKey |
QEJBZGVMIACMJY-UPVQGACJSA-N
|
|||||
| Pharmaceutical Properties |
Molecule Weight
|
630.772
|
Polar area
|
217.53
|
||
|
Complexity
|
1183.604352
|
xlogp Value
|
1.2606
|
|||
|
Heavy Count
|
44
|
Rot Bonds
|
18
|
|||
|
Hbond acc
|
9
|
Hbond Donor
|
8
|
|||
Each Antibody-drug Conjugate Related to This Linker
Full Information of The Activity Data of The ADC(s) Related to This Linker
H- (A114C)-#19 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | < 12.77 ng/mL | Positive Her2 expression (Her2+++/++) | ||
| Method Description |
Her2-Target expressing MDA-MB-361-DYT2 (breast cancer) cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e., no antibody conjugated to the drug) in duplicate at 37 concentrations.
|
||||
| In Vitro Model | Breast adenocarcinoma | MDA-MB-361-DYT2 cells | CVCL_0620 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
31.09 ng/mL
|
Positive Her2 expression (Her2+++/++) | ||
| Method Description |
Her2-Target expressing (BT474 (breast cancer), N87 (gastric cancer), MDA-MB-361-DYT2 (breast cancer)) or Her2-non-expressing (MDA-MB-468, HT29) cells, or CD33-target expressing HL60, HEL92.1.7, NB4 or CD33-non-expressing (Raji) cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e., no antibody conjugated to the drug) in duplicate at 37 concentrations.
Click to Show/Hide
|
||||
| In Vitro Model | Invasive breast carcinoma | BT-474 cells | CVCL_0179 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
37931 ng/mL
|
Negative Her2 expression (Her2-) | ||
| Method Description |
Her2-non-expressing HT29) cells were seeded in 96-well cell culture plates for 24 hours before treatment. Cells were treated with 3-fold serially diluted antibody-drug conjugates or free compounds (i.e., no antibody conjugated to the drug) in duplicate at 31 concentrations.
|
||||
| In Vitro Model | Colon adenocarcinoma | HT29 cells (HER2-) | CVCL_0320 | ||
References